C4 Therapeutics, Inc. (NASDAQ:CCCC) Holdings Raised by Millennium Management LLC

Millennium Management LLC boosted its holdings in C4 Therapeutics, Inc. (NASDAQ:CCCC - Free Report) by 1,548.3% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 360,125 shares of the company's stock after buying an additional 338,277 shares during the quarter. Millennium Management LLC owned 0.51% of C4 Therapeutics worth $1,296,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Sei Investments Co. bought a new stake in shares of C4 Therapeutics during the 4th quarter worth $45,000. Kazazian Asset Management LLC purchased a new stake in shares of C4 Therapeutics during the fourth quarter valued at $51,000. Lazard Asset Management LLC purchased a new stake in shares of C4 Therapeutics during the fourth quarter valued at $81,000. Y Intercept Hong Kong Ltd acquired a new position in shares of C4 Therapeutics in the 4th quarter valued at $83,000. Finally, Intech Investment Management LLC boosted its position in shares of C4 Therapeutics by 11.1% in the 4th quarter. Intech Investment Management LLC now owns 30,150 shares of the company's stock valued at $109,000 after purchasing an additional 3,024 shares during the period. Institutional investors own 78.81% of the company's stock.

Analyst Upgrades and Downgrades

Separately, UBS Group raised shares of C4 Therapeutics to a "hold" rating in a research note on Friday, February 14th.

C4 Therapeutics Stock Up 17.7%

Shares of CCCC traded up $0.26 during mid-day trading on Friday, reaching $1.73. The company's stock had a trading volume of 1,280,774 shares, compared to its average volume of 1,378,321. The company has a market cap of $122.84 million, a price-to-earnings ratio of -1.02 and a beta of 2.93. The business has a fifty day moving average of $1.41 and a 200 day moving average of $2.70. C4 Therapeutics, Inc. has a 1 year low of $1.09 and a 1 year high of $7.66.

C4 Therapeutics (NASDAQ:CCCC - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.48) by $0.11. C4 Therapeutics had a negative return on equity of 42.45% and a negative net margin of 313.35%. The firm had revenue of $7.20 million for the quarter, compared to analyst estimates of $3.54 million. On average, analysts predict that C4 Therapeutics, Inc. will post -1.52 earnings per share for the current year.

C4 Therapeutics Profile

C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.